Bristol Myers Squibb signed a $15.2 billion deal with China’s Hengrui Medicine for 13 early-stage drug programmes, as Big Pharma’s patent cliff makes Chinese innovation the fastest path to commercial survival — even as the BIOSECURE Act tries to decouple the two countries’ biotech sectors.
TL;DR
Bristol Myers Squibb has signed a deal worth up to 15.2 billion dollars with Jiangsu Hengrui Medicine, China’s largest pharmaceutical company by market capitalisation. The agreement covers 13 early-stage drug programmes across oncology, haematology, and immunology. None of the drugs have entered human clinical trials. The deal was announced on the same day that President Trump flew to Beijing for his first state visit to China in his second term.
The timing is coincidence. The economics are not. Bristol Myers Squibb is staring at a patent cliff that will strip roughly 300 billion dollars in revenue from the global pharmaceutical industry by 2030. Its own blockbusters, Opdivo and Eliquis, together generating more than 22 billion dollars in annual sales, face loss of exclusivity around 2028. The company needs new molecules. It cannot discover them fast enough on its own. China can.
BMS will pay Hengrui 600 million dollars at closing, 175 million on the first anniversary, and a contingent 175 million in 2028, totalling 950 million dollars in structured payments through the near term. The remaining 14.25 billion is in development, regulatory, and commercial milestones. BMS gets exclusive worldwide rights to Hengrui’s four oncology and haematology assets outside mainland China, Hong Kong, and Macau. Hengrui gets exclusive rights to four BMS immunology assets inside those territories. The two companies will jointly discover and develop five additional programmes using Hengrui’s discovery engine.
The structure tells the story. BMS is not acquiring Hengrui. It is licensing Hengrui’s research output. The American company with the patent cliff is paying the Chinese company with the pipeline. The transaction is expected to close in the third quarter of 2026, subject to antitrust review. Hengrui’s share price rose on the announcement. BMS’s did not fall.
Hengrui is not the Chinese pharmaceutical company that American executives imagined a decade ago. It is not a generics manufacturer. It operates more than 90 in-house therapies in clinical development across 400 clinical trials, including over 20 international studies. It is the only Chinese pharmaceutical company to rank among Citeline’s global top 10 pharma pipelines, alongside Pfizer, Roche, and AstraZeneca. Its R&D spending exceeded 2.22 billion yuan in the first quarter of 2026 alone, representing 27 per cent of revenue. It has 30 commercialised drugs in China and 20 approved in the EU, the US, and Japan.
The company’s market capitalisation is roughly 54.6 billion dollars. It reported first-quarter profit growth of 21.8 per cent. Its pipeline spans oncology, cardiometabolic diseases, immunology, respiratory conditions, and neuroscience. The deal with BMS is not Hengrui’s first major international licensing agreement. It is the largest. And it comes after a year in which Chinese drug companies collectively struck 137.7 billion dollars in out-licensing deals, a figure that was nearly tenfold the total recorded in 2021.
The pharmaceutical industry’s patent cliff is not a future event. It is underway. BMS reported full-year 2025 revenues of 48.2 billion dollars, down from 48.3 billion the year before, and guided 2026 revenues between 46 billion and 47.5 billion dollars. Legacy product revenue fell 15 per cent to 21.8 billion in 2025. Pomalyst sales declined from 3.55 billion to 2.73 billion as generic competition arrived. The company’s growth portfolio, led by Opdivo, Breyanzi, Reblozyl, and Camzyos, is generating 16 per cent year-over-year increases, but the growth must outrun the erosion.
BMS is not alone. The industry faces more than 300 billion dollars in revenue losing patent protection between 2025 and 2030. Merck’s Keytruda, the world’s best-selling drug at 29.5 billion dollars in 2024, hits its own cliff. Pfizer is racing to launch obesity drugs by 2028 to offset expiring franchises. The entire sector is searching for the same thing: molecules. The companies that have them are increasingly Chinese.
AstraZeneca signed an 18.5 billion dollar deal with China’s CSPC Pharmaceutical in January for eight obesity and diabetes drug candidates. AbbVie agreed to a 5.6 billion dollar cancer deal with RemeGen. Chinese companies accounted for roughly one third of all global licensing spending in 2025, up from a fraction of that five years earlier. The average upfront payment for a licensing deal with a Chinese company rose from 52 million dollars in 2022 to 172 million in early 2026. The bargain era is over. Chinese biotechs know the value of what they have built.
Stanford’s 2026 AI Index found that China has narrowed the performance gap with the US to 2.7 per cent while spending 23 times less on AI investment. The same dynamic is playing out in pharmaceutical R&D. Chinese clinical trial output surpassed the US for the first time in 2025. Chinese biotechs now account for nearly 70 per cent of global AI-driven drug discovery patent filings. The country is producing more drug candidates, faster, at lower cost, than the Western pharmaceutical companies that need them most.
The BIOSECURE Act became law in December 2025. It restricts federal agencies from contracting with designated Chinese biotechnology companies. The law was designed to reduce American dependence on Chinese biotech infrastructure, particularly contract research and manufacturing organisations like WuXi AppTec and WuXi Biologics. The intention was to decouple the US pharmaceutical supply chain from China.
BMS’s 15.2 billion dollar deal with Hengrui is not covered by the BIOSECURE Act. The law targets government contracts, not private licensing agreements. But the contradiction is structural. Congress passed legislation to restrict Chinese biotech access on national security grounds while the largest American pharmaceutical companies are signing record-breaking deals with Chinese drug developers because they cannot fill their pipelines without them. The decoupling strategy that works in semiconductors and AI chips does not work in drug discovery, because the molecules that Chinese scientists are finding are the molecules that American patients need.
Foreign automakers have been forced to partner with Chinese technology companies because they cannot develop competitive software fast enough on their own. The same logic now applies to pharmaceuticals. BMS is not signing a 15.2 billion dollar deal because it wants to. It is signing it because the patent cliff has made Chinese innovation the fastest path to commercial survival.
The deal was announced as Trump’s delegation, including Elon Musk, Tim Cook, and Larry Fink, prepared to land in Beijing for three days of talks on trade, technology, and the Iran war. Semiconductor export controls, rare earth restrictions, and tariff extensions dominate the summit agenda. Pharmaceuticals are not on the official programme. But the BMS-Hengrui deal illustrates a reality that the trade negotiators on both sides already understand: American companies are dependent on Chinese innovation in ways that export controls cannot reach.
China’s manufacturing supply chain is pivoting from smartphones to humanoid robots, from consumer electronics to autonomous systems, from generics to novel drug candidates. The pattern is the same across industries. Chinese companies that were once low-cost manufacturers are now high-value innovators, and the Western companies that once outsourced production to them are now licensing intellectual property from them. The power dynamic has inverted.
American capital is flowing into R&D at industrial scale, with billions pouring into AI laboratories, biotech platforms, and drug discovery engines. But the capital is increasingly being deployed to access Chinese research rather than replace it. BMS’s structured payments to Hengrui, 950 million dollars through 2028 before a single drug reaches clinical trials, represent the price of admission to a pipeline that took decades of Chinese R&D investment to build.
China’s regulatory environment is maturing alongside its innovation capacity, with governance frameworks for AI, biotech, and pharmaceutical research developing in parallel with the scientific output. The Chinese pharmaceutical industry that American companies are now licensing from is not the unregulated manufacturing sector of the early 2000s. It is a state-supported, globally competitive, scientifically rigorous ecosystem that produces drug candidates that meet FDA standards, which is why BMS is paying 15.2 billion dollars for access to 13 of them.
The deal will close this summer. The drugs will take years to reach patients, if they work at all. Thirteen early-stage programmes with no human clinical data carry enormous risk. But Bristol Myers Squibb calculated that the risk of not signing was greater than the risk of signing. The patent cliff does not wait for geopolitics. The largest pharmaceutical deal with a Chinese company in history was announced on the same day the American president arrived in Beijing to discuss decoupling. One conversation is about separating the two economies. The other is about why that is no longer possible.
You must be logged in to post a comment Login